Innovative
Monoclonal Antibodies
Against Small Molecules
& Transmembrane Proteins

Immunoglobulin SuperFamily (IgSF) therapeutic antibodies

Immunoglobulin SuperFamily (IgSF) therapeutic antibodies · 04. December 2021

CD2, the missed opportunity for monoclonal antibody therapy?

SYnAbs unique therapeutic rat monoclonal antibodies targeting CD2 giving birth to Siplizumab and LO-CD2b for T cell depletion. Unique DNA, syngeneic cell immunization strategies to generate monoclonals against transmembrane proteins.

Monoclonal antibodies to human CD cell surface antigens

SYnAbs generates innovative functional monoclonals against clusters of differentiation markers, IgG superfamily, and C-type lectin-like receptors (CLRs). Discover how SYnAbs generate Siplizumab anti-human CD2a antibody and other transmembrane effector monoclonals.

TRAIL, the new Grail?

TRAIL and TRAIL receptors (tumor-necrosis-factor related apoptosis-inducing ligand) SYnabs unique antibodies